<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03135496</url>
  </required_header>
  <id_info>
    <org_study_id>PI2016_843_0029</org_study_id>
    <nct_id>NCT03135496</nct_id>
  </id_info>
  <brief_title>Evaluation of Endothelial Dysfunction During Aortic Valvular Replacement by Bioprosthesis With and Without Extracorporeal Circulation</brief_title>
  <acronym>DYVA2</acronym>
  <official_title>Evaluation of Endothelial Dysfunction During Aortic Valvular Replacement by Bioprosthesis With and Without Extracorporeal Circulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with aortic stenosis present many risk factors for endothelial dysfunction (arterial&#xD;
      hypertension, arteriosclerosis, dyslipidemia, chronic renal insufficiency, etc.). It is&#xD;
      likely that a significant number of patients suffer from pre-existing endothelial dysfunction&#xD;
      that can be evaluated by a molecular approach.&#xD;
&#xD;
      To date, the replacement of the aortic valve can be performed by surgery with extracorporeal&#xD;
      circulation (CEC) or percutaneous (Transcatheter Aortic Valve ImplantationTAVI) without CEC.&#xD;
&#xD;
      Two recent studies have demonstrated a sustained improvement in endothelial function with&#xD;
      TAVI. On the contrary, studies have demonstrated that post-operative complications&#xD;
      (coagulopathy, capillary leak syndrome, acute vasoplastic disorder and acute renal failure)&#xD;
      after surgery with extracorporeal circulation (CEC) could be the result of the interaction&#xD;
      between pre-existing endothelial dysfunction And the &quot;operative&quot; aggression associated with&#xD;
      the CEC.&#xD;
&#xD;
      Thus, patients with preexisting involvement of endothelial function would develop vascular&#xD;
      dysfunction after valvular replacement due to &quot;endothelial activation&quot; related to CEC. This&#xD;
      phenomenon would not exist in TAVI, and would explain the absence of so-called vascular&#xD;
      dysfunction complications (Systemic inflammatory response syndrome, vasoplastic syndrome,&#xD;
      disseminated intravascular coagulation).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 5, 2017</start_date>
  <completion_date type="Actual">January 4, 2019</completion_date>
  <primary_completion_date type="Actual">January 4, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of the variation of the following endothelial function markers: angiopoetin 1 and 2 depending on whether or not extracorporeal circulation</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">51</enrollment>
  <condition>Endothelial Dysfunction</condition>
  <condition>Aortic Valve Disease</condition>
  <arm_group>
    <arm_group_label>Surgery with CEC</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Without CEC</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Study of endothelial function biological markers</intervention_name>
    <description>Study of endothelial function biological markers</description>
    <arm_group_label>Surgery with CEC</arm_group_label>
    <arm_group_label>Without CEC</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        (Angiopoietin 1 and 2) in two types of populations: one with CEC and one without CEC&#xD;
        (TAVI).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient â‰¥ 18 years.&#xD;
&#xD;
          -  Patient operated on aortic valvular replacement by bioprosthesis in surgery + CEC or&#xD;
             TAVI&#xD;
&#xD;
          -  Signed consent.&#xD;
&#xD;
          -  Affiliation to Social Security&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any other cardiac surgery&#xD;
&#xD;
          -  Mechanical aortic valve replacement&#xD;
&#xD;
          -  Permanent Ac / Fa.&#xD;
&#xD;
          -  Pregnant woman.&#xD;
&#xD;
          -  Curative anticoagulation (AVK, NANCO, heparin).&#xD;
&#xD;
          -  Patient under tutelage or curatelle.&#xD;
&#xD;
          -  Refusal of the patient.&#xD;
&#xD;
          -  Participation in another study.&#xD;
&#xD;
          -  Preoperative sepsis&#xD;
&#xD;
          -  Minor or adult, under guardianship or curatorship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Amiens Picardie</name>
      <address>
        <city>Amiens</city>
        <state>Picardie</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 27, 2017</study_first_submitted>
  <study_first_submitted_qc>April 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2017</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

